Stifel Financial Corp Sells 1,202 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Stifel Financial Corp reduced its stake in Immunocore Holdings plc (NASDAQ:IMCR) by 6.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 18,251 shares of the company’s stock after selling 1,202 shares during the quarter. Stifel Financial Corp’s holdings in Immunocore were worth $568,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC lifted its stake in shares of Immunocore by 40.4% in the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after buying an additional 1,461 shares during the last quarter. Connective Portfolio Management LLC bought a new position in Immunocore in the 3rd quarter worth $218,000. China Universal Asset Management Co. Ltd. lifted its position in Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after acquiring an additional 3,053 shares during the last quarter. XTX Topco Ltd bought a new stake in Immunocore during the second quarter valued at about $303,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Immunocore in the third quarter valued at about $406,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Price Performance

NASDAQ:IMCR opened at $30.22 on Friday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The firm has a market cap of $1.51 billion, a PE ratio of -31.81 and a beta of 0.73. Immunocore Holdings plc has a 12 month low of $27.69 and a 12 month high of $76.98. The company’s 50-day moving average price is $31.77 and its two-hundred day moving average price is $34.37.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. During the same period in the previous year, the business earned ($0.59) EPS. Immunocore’s revenue was up 23.7% compared to the same quarter last year. On average, equities analysts anticipate that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $72.00 to $38.00 in a research report on Monday, November 11th. UBS Group initiated coverage on shares of Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 target price on the stock. Needham & Company LLC reduced their price target on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating for the company in a report on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Thursday, October 24th. Finally, Guggenheim lowered shares of Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $65.64.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.